Telomir Pharmaceuticals, Inc.
TELO
$4.58
-$0.45-8.95%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.13% | -309.30% | 76.83% | 32.94% | -445.04% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 483.29% | 0.00% |
| Total Other Non-Cash Items | -54.38% | -- | -- | -- | 55,670.90% |
| Change in Net Operating Assets | -18.36% | 266.80% | -215.38% | -201.74% | 102.19% |
| Cash from Operations | 39.57% | 34.17% | 21.48% | -78.38% | 45.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -200.00% | -- | -- | -31.70% |
| Total Debt Repaid | 100.00% | -- | 100.00% | -177.69% | 200.00% |
| Issuance of Common Stock | -- | -- | -100.00% | 6,381.11% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -159.23% | -135.80% |
| Cash from Financing | 2,311.73% | -135.42% | -97.46% | 379.97% | -45.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.12% | 24.53% | -142.48% | 272,858.33% | 90.16% |
